Chief
Brigitte C. Widemann, M.D.
Deputy Chief
Carol J. Thiele, Ph.D.
ncipediatrics@mail.nih.gov
Building 10, Room 1W-3750
Bethesda, MD 20892
240-760-6560

The Pediatric Oncology Branch is dedicated to improving outcomes for children and young adults with cancer and genetic tumor predisposition syndromes. We conduct translational research that spans basic science to clinical trials. Our clinical studies are performed in an environment that supports our patient’s medical and emotional needs, alongside cutting edge scientific research.

Whether you are a referring physician, family member or patient with childhood cancer or neurofibromatosis, or are interested in training at the Pediatric Oncology Branch, we hope that this website will provide the information you need to access our programs.

Brigitte C. Widemann, M.D.Brigitte C. Widemann, M.D.
Chief, Pediatric Oncology Branch
 
divider line
  • Refer a PatientRefer a Patient

    Physicians should contact the Pediatric Oncology Branch by calling 240-760-6403 or 1-833-248-0479 or email NCIPOBReferrals@mail.nih.gov

  • Clinical TrialsClinical Trials

    We conduct clinical trials in acute lymphoblastic leukemia, pediatric sarcomas, neuroblastoma, brain tumors, malignant melanoma, neurofibromatosis and Phase I trials.

  • Pediatric Oncology Fellowship - 2012 fellowsFellowship

    The Pediatric Hematology Oncology Fellowship is a joint program of the Pediatric Oncology Branch, NCI, NIH and Johns Hopkins University.

  • NewsTravis with Zilly the therapy dog

    MEK inhibitor selumetinib granted breakthrough designation by FDA. 
    Read more...

Our investigators and physicians realize that many challenges remain in the treatment of childhood cancers and genetic tumor predisposition syndromes but we are committed to improving outcomes for children and young adults with these diseases through cutting-edge basic and clinical research. Patients with cancer, neurofibromatosis type 1 (NF1), NF2 or other diseases under study who are enrolled on Branch clinical trials may receive therapy at the NIH Clinical Center.

Pediatric Oncology: A Tour for New Patients
Link to audio described version here.

Our clinical programs and trials span early treatment studies with new targeted agents including small molecules, monoclonal antibodies and immunotoxins, immunotherapy including tumor vaccines, and bone marrow transplantation, to studies aimed at improving our understanding of childhood cancers and the conditions that predispose children to cancer. Our multidisciplinary teams specialize in the study and treatment of:

Support Services

The treatment of a childhood cancer presents extraordinary psychological, emotional and social challenges to the entire family. We offer a variety of support services to help patients and their families adapt and mobilize resources during treatment for these diseases. At the heart of these services is the personal commitment of every clinical team member to understand each young patient as a unique individual with specific needs. Team members collaborate with parents at each step in the process to be attentive to the quality of life of all family members, including siblings.  

 

refer a patientReferrals

Physicians, patients, or family members may contact the Pediatric Oncology Branch from 8:30 AM to 5:00 PM, Monday-Friday:

Administrative Staff:

Fidelia Acevedo, Program Assistant
240-858-3844

Tiffany Prout, Administrative Assistant (Contr.)
240-276-5130

Donna Shiels, Administrative Assistant (Contr.)
240-858-3831

camp fantasticRelated Links

 

pob traineesTraining Opportunities

 

Trainees and Featured Alumni

  • James Morrow – MD/PhD, Graduate Student
  • Adrienne Long – MD/PhD, Graduate Student
  • Meera Murgabi – PhD, Postdoctoral Fellow
  • Jerry Jaboin – MD, PhD, Assistant Professor, Radiation Oncology, Washington University, St. Louis
  • AeRang Kim – MD, PhD, Assistant Professor, George Washington University and Attending Physician at the Center for Cancer and Blood Disorders at the Children’s National Medical Center

Travis with Zilly the therapy dogMEK inhibitor selumetinib is granted breakthrough designation by FDA to treat children with neurofibromatosis type 1 (NF1)

April 2019

The U.S. Food and Drug Administration granted a breakthrough therapy designation for the MEK 1/2 inhibitor selumetinib for use in pediatric patients aged 3 years and older with symptomatic neurofibromatosis type 1 (NF1) and/or inoperable plexiform neurofibromas. The breakthrough designation was granted based on evidence from a phase II clinical trial, led by the POB. The FDA breakthrough designation is designed to accelerate the development and approval of drugs that show substantial improvement over currently available treatment. Read more.


  • Dr. Karlyne Reilly, Ph.D., speaks at the Future of Healthcare Summit held by The Hill

    June 2019

    Dr. Karlyne Reilly participated in a panel on rare disease at the Future of Healthcare Summit, an event organized by The Hill magazine. She spoke about the challenges in rare disease and rare cancer research, and the importance of collaboration and innovation to develop therapies and get them to the patients. Watch the panel discussion here: https://buff.ly/326wUnX.

  • Congressional staff visit the POB

    May 2019

    On May 29, 2019, Congressional staff visited the POB and participated in a roundtable discussion about childhood cancer research with NCI pediatric oncology experts. Congressional staff also toured labs within the POB and met with patients and families at the Children’s Inn at NIH. Nine bipartisan and bicameral staffers interested in childhood cancer research were present for the visit. 

  • Dr. Nirali Shah, M.D., and Dr. Lori Wiener, Ph.D., speak at the Children and Cancer summit hosted by The Atlantic

    May 2019

    On May 22, 2019, the Atlantic magazine hosted a summit on Children and Cancer. Dr. Nirali Shah, M.D. discussed her work on immunotherapy: Watch here. Dr. Lori Wiener, Ph.D. discussed her work on psychosocial standards of care for children and young adults with cancer: Watch here.

  • Dr. Udo Rudloff, M.D., Ph.D., discusses his research on CDH1 germline mutations in a Bloomberg podcast

    May 2019

    Dr. Udo Rudloff, M.D., Ph.D. is featured on a recent Bloomberg Prognosis podcast episode entitled “Should We Be Scared of Our DNA?” He discusses the risks of developing diseases from genetic mutations. He also explains his work on the CDH1 germline mutations and the associated risk of hereditary diffuse gastric cancer (HDGC). Listen the full podcast online here.

About

The Pediatric Oncology Branch is dedicated to improving outcomes for children and young adults with cancer and genetic tumor predisposition syndromes. We conduct translational research that spans basic science to clinical trials. Our clinical studies are performed in an environment that supports our patient’s medical and emotional needs, alongside cutting edge scientific research.

Whether you are a referring physician, family member or patient with childhood cancer or neurofibromatosis, or are interested in training at the Pediatric Oncology Branch, we hope that this website will provide the information you need to access our programs.

Brigitte C. Widemann, M.D.Brigitte C. Widemann, M.D.
Chief, Pediatric Oncology Branch
 
divider line
  • Refer a PatientRefer a Patient

    Physicians should contact the Pediatric Oncology Branch by calling 240-760-6403 or 1-833-248-0479 or email NCIPOBReferrals@mail.nih.gov

  • Clinical TrialsClinical Trials

    We conduct clinical trials in acute lymphoblastic leukemia, pediatric sarcomas, neuroblastoma, brain tumors, malignant melanoma, neurofibromatosis and Phase I trials.

  • Pediatric Oncology Fellowship - 2012 fellowsFellowship

    The Pediatric Hematology Oncology Fellowship is a joint program of the Pediatric Oncology Branch, NCI, NIH and Johns Hopkins University.

  • NewsTravis with Zilly the therapy dog

    MEK inhibitor selumetinib granted breakthrough designation by FDA. 
    Read more...

Referrals

refer a patientReferrals

Physicians, patients, or family members may contact the Pediatric Oncology Branch from 8:30 AM to 5:00 PM, Monday-Friday:

Administrative Staff:

Fidelia Acevedo, Program Assistant
240-858-3844

Tiffany Prout, Administrative Assistant (Contr.)
240-276-5130

Donna Shiels, Administrative Assistant (Contr.)
240-858-3831

camp fantasticRelated Links

 

For Patients

Our investigators and physicians realize that many challenges remain in the treatment of childhood cancers and genetic tumor predisposition syndromes but we are committed to improving outcomes for children and young adults with these diseases through cutting-edge basic and clinical research. Patients with cancer, neurofibromatosis type 1 (NF1), NF2 or other diseases under study who are enrolled on Branch clinical trials may receive therapy at the NIH Clinical Center.

Pediatric Oncology: A Tour for New Patients
Link to audio described version here.

Our clinical programs and trials span early treatment studies with new targeted agents including small molecules, monoclonal antibodies and immunotoxins, immunotherapy including tumor vaccines, and bone marrow transplantation, to studies aimed at improving our understanding of childhood cancers and the conditions that predispose children to cancer. Our multidisciplinary teams specialize in the study and treatment of:

Support Services

The treatment of a childhood cancer presents extraordinary psychological, emotional and social challenges to the entire family. We offer a variety of support services to help patients and their families adapt and mobilize resources during treatment for these diseases. At the heart of these services is the personal commitment of every clinical team member to understand each young patient as a unique individual with specific needs. Team members collaborate with parents at each step in the process to be attentive to the quality of life of all family members, including siblings.  

 

Teams

For Trainees

pob traineesTraining Opportunities

 

Trainees and Featured Alumni

  • James Morrow – MD/PhD, Graduate Student
  • Adrienne Long – MD/PhD, Graduate Student
  • Meera Murgabi – PhD, Postdoctoral Fellow
  • Jerry Jaboin – MD, PhD, Assistant Professor, Radiation Oncology, Washington University, St. Louis
  • AeRang Kim – MD, PhD, Assistant Professor, George Washington University and Attending Physician at the Center for Cancer and Blood Disorders at the Children’s National Medical Center

Our Science

News

Travis with Zilly the therapy dogMEK inhibitor selumetinib is granted breakthrough designation by FDA to treat children with neurofibromatosis type 1 (NF1)

April 2019

The U.S. Food and Drug Administration granted a breakthrough therapy designation for the MEK 1/2 inhibitor selumetinib for use in pediatric patients aged 3 years and older with symptomatic neurofibromatosis type 1 (NF1) and/or inoperable plexiform neurofibromas. The breakthrough designation was granted based on evidence from a phase II clinical trial, led by the POB. The FDA breakthrough designation is designed to accelerate the development and approval of drugs that show substantial improvement over currently available treatment. Read more.


  • Dr. Karlyne Reilly, Ph.D., speaks at the Future of Healthcare Summit held by The Hill

    June 2019

    Dr. Karlyne Reilly participated in a panel on rare disease at the Future of Healthcare Summit, an event organized by The Hill magazine. She spoke about the challenges in rare disease and rare cancer research, and the importance of collaboration and innovation to develop therapies and get them to the patients. Watch the panel discussion here: https://buff.ly/326wUnX.

  • Congressional staff visit the POB

    May 2019

    On May 29, 2019, Congressional staff visited the POB and participated in a roundtable discussion about childhood cancer research with NCI pediatric oncology experts. Congressional staff also toured labs within the POB and met with patients and families at the Children’s Inn at NIH. Nine bipartisan and bicameral staffers interested in childhood cancer research were present for the visit. 

  • Dr. Nirali Shah, M.D., and Dr. Lori Wiener, Ph.D., speak at the Children and Cancer summit hosted by The Atlantic

    May 2019

    On May 22, 2019, the Atlantic magazine hosted a summit on Children and Cancer. Dr. Nirali Shah, M.D. discussed her work on immunotherapy: Watch here. Dr. Lori Wiener, Ph.D. discussed her work on psychosocial standards of care for children and young adults with cancer: Watch here.

  • Dr. Udo Rudloff, M.D., Ph.D., discusses his research on CDH1 germline mutations in a Bloomberg podcast

    May 2019

    Dr. Udo Rudloff, M.D., Ph.D. is featured on a recent Bloomberg Prognosis podcast episode entitled “Should We Be Scared of Our DNA?” He discusses the risks of developing diseases from genetic mutations. He also explains his work on the CDH1 germline mutations and the associated risk of hereditary diffuse gastric cancer (HDGC). Listen the full podcast online here.

RT : Registration is open for symposium focused on the impact of personal control of sharing to res… https://t.co/aPLdK8NBza

RT : Have questions about the . Check out the answers to some of the most frequently asked questions abo… https://t.co/q6ccwrSCxu

There's only ONE more day to submit your for the Data Initiative! Help develop reco… https://t.co/6d46KTyOk4

The Data Initiative emphasizes the value of - building on research conducted across t… https://t.co/pVWVEOd0DE

RT : Please share! Registration is open for symposium focused on the impact of personal control of https://t.co/p3q4nXBcoI

RT : Our physicians develop and lead in the world’s largest dedicated research hospital https://t.co/puY2lKM3un

RT : One of the highlights of the summer each year is seeing the photos and hearing stories from ’s… https://t.co/y0i1zq7EI7